Therapies and methods to treat TLR2-mediated diseases and disorders
AssigneeThe Regents of the University of California
InventorsJoseph L. Witztum, Sotirios Tsimikas, Xuchu Que
Life of this patent
Estimating the term…
Abstract
The disclosure provides for methods and treatments of TLR2-mediated diseases and disorders comprising administering an antibody, antibody fragment, or polypeptide that binds to and inhibits the biological activity of oxidized phospholipids.
Claims14
A method of treating a subject with Kawasaki disease, comprising administering to the subject a therapeutically effective amount of an antibody, antibody fragment, or polypeptide that binds specifically to an oxidative phospholipid (OxPL), wherein the antibody, antibody fragment or polypeptide inhibits a biological activity of the OxPL;
- and wherein the antibody, antibody fragment or polypeptide comprises:
- a variable heavy chain domain (VH) comprising the complementarity determining regions (CDRs) of the VH amino acid sequence set forth in SEQ ID NO:2;
- and a variable light chain domain (VL) comprising the CDRs of the VL amino acid sequence set forth in SEQ ID NO:2 or 4.
Dependencies are inferred from the claim text.